학술논문

SUSTAINED SURVIVAL ADVANTAGE AFTER A MEDIAN FOLLOW-UP OF 5 YEARS FOR IMMUNO-CHEMOTHERAPY (R-MCP) VERSUS CHEMOTHERAPY ALONE (MCP) IN ADVANCED FOLLICULAR LYMPHOMA - UPDATE OF THE OSHO#39 TRIAL
Document Type
Journal
Source
HAEMATOLOGICA; JUN 15 2010, 95 p239-p239, 1p. Supplement: 2
Subject
Language
English
ISSN
03906078